OCERA THERAPEUTICS,INC. (NASDAQ:OCRX) Files An 8-K Other Events
Item 8.01 Other Events.
On December7, 2016, Ocera Therapeutics,Inc. (the Company) issued
a press release announcing the completion of enrollment of
STOP-HE, the Companys Phase 2b clinical trial of OCR-002 in
hospitalized patients with hepatic encephalopathy. The full text
of the press release is filed as Exhibit99.1 to this Current
Report on Form8-K and is incorporated herein by reference.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits
|
ExhibitNo. |
|
Description |
|
99.1 |
Press release of Ocera Therapeutics,Inc. dated December7, |
About OCERA THERAPEUTICS, INC. (NASDAQ:OCRX)
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge. OCERA THERAPEUTICS, INC. (NASDAQ:OCRX) Recent Trading Information
OCERA THERAPEUTICS, INC. (NASDAQ:OCRX) closed its last trading session 00.00 at 2.35 with 71,392 shares trading hands.